Why the study?
Does multimodality therapy improve survival in patients with primary cardiac sarcoma?
Does multimodality therapy improve survival in patients with primary cardiac sarcoma?
Multimodality therapy including surgery, radiation, and chemotherapy is associated with improved survival in patients with primary cardiac sarcoma, though findings may be limited by selection bias.
Answers are grounded in this paper and cite their sources.
May support multimodality therapy in cardiac sarcoma but should not change practice; leaves open confirmation in prospective trials.
Cardiac sarcoma is a lethal tumor with an EMS of 25 months. The tumor histology could be a possible predictor of better survival. Although selection bias may have been present, multimodality therapy (surgery, radiation therapy, and chemotherapy) was associated with improved survival.
No takes yet. Share an insight, caveat, or question.
Randhawa et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: